The Consumers Health Forum has expressed its concerns about the issue of substitution of biological medicines with biosimilars, at a meeting called by the Pharmaceutical Benefits Advisory Committee.
CEO of the Forum, Leanne Wells, says that at the meeting there was “a consistency in the concern and opposition from clinical and consumer groups concerning the ‘a’ flagging of biosimilars and substituting them at the pharmacy level”.
“There was also consistency in the view that decisions to substitute should only be made in the context of the therapeutic doctor-patient relationship,” she says.
“We await with interest the response from the PBAC.
“This is a really complex, evolving area of medicine and underlines the need for clinicians, dispensers and patients to have access to independent and authoritative information.”